Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

Published:2016-02-22 Issue:7 Volume:19 Page:pyw018
ISSN:1461-1457
Container-title:International Journal of Neuropsychopharmacology
language:en
Short-container-title:IJNPPY

Author:

Savitz Adam J.,Xu Haiyan,Gopal Srihari,Nuamah Isaac,Ravenstijn Paulien,Janik Adam,Schotte Alain,Hough David,Fleischhacker Wolfgang W.

Funder

Janssen Research & Development

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology

Reference22 articles.

1. Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics;Alphs;Neuropsychiatr Dis Treat,2013

2. Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus

3. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia

4. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

5. A Comparison of Risperidone and Haloperidol for the Prevention of Relapse in Patients with Schizophrenia

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical effectiveness of paliperidone palmitate 3‐monthly and 1‐monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database;Neuropsychopharmacology Reports;2024-09-11

2. Three-Year Outcomes of 6-Month Paliperidone Palmitate in Adults With Schizophrenia;JAMA Network Open;2024-07-17

3. Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I);European Journal of Drug Metabolism and Pharmacokinetics;2024-05-15

4. Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults;Expert Review of Neurotherapeutics;2024-03-06

5. Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations;International Journal of Neuropsychopharmacology;2024-02-01